Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals announced the details of its upcoming annual general meeting, scheduled for November 19, 2025, to be held both in-person and virtually. Shareholders are encouraged to participate by submitting proxy forms and questions in advance, with the company providing online resources to facilitate engagement. This move reflects the company’s commitment to shareholder engagement and transparency, potentially impacting its operational strategies and stakeholder relations positively.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a company operating in the biopharmaceutical industry, focusing on developing and commercializing therapies for unmet medical needs. The company’s primary products and services revolve around innovative treatments, with a market focus on addressing specific health conditions that lack effective solutions.
YTD Price Performance: 6.67%
Average Trading Volume: 997,600
Technical Sentiment Signal: Buy
Current Market Cap: A$169.4M
Learn more about PAR stock on TipRanks’ Stock Analysis page.